Skip to main content Back to Top
Advertisement

11/25/2019

Clindamycin Phosphate Injection

Products Affected - Description

    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL ADD-Vantage vial, 25 count, NDC 00009-6582-01
    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL ADD-Vantage vial, 25 count, NDC 00009-3124-03
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL ADD-Vantage vial, 25 count, NDC 00009-3447-03
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL vial, 25 count, NDC 00009-0902-18
    • Clindamycin phosphate injection, Akorn, 600 mg/50 mL, premixed bottle, 1 count, NDC 17478-0121-50
    • Clindamycin phosphate injection, Akorn, 900 mg/50 mL, premixed bottle, 1 count, NDC 17478-0122-50
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL ADD-Vantage vial, 25 count, NDC 72611-0762-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL vial, 25 count, NDC 72611-0634-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL ADD-Vantage vial, 25 count, NDC 72611-0767-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL ADD-Vantage vial, 25 count, NDC 72611-0769-25 - discontinued
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 4 mL vial, 25 count, NDC 63323-0282-04
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 60 mL vial, 1 count, NDC 63323-0282-60
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 2 mL vial, 25 count, NDC 25021-0115-02
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 4 mL vial, 25 count, NDC 25021-0115-04
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 6 mL vial, 25 count, NDC 25021-0115-06

Reason for the Shortage

    • Alvogen injectable generic products including clindamycin are being marketed under the brand, Almaject Inc., as of October 1, 2019. The NDC numbers for these products have changed.
    • Akorn did not provide a reason for the shortage.
    • Baxter has clindamycin injection available.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Pfizer did not provide a reason for the shortages. Pfizer discontinued Cleocin premixed bags in 2018.
    • Sagent did not provide a reason for the shortage.
    • Sandoz did not provide a reason for the shortage.

Available Products

    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL vial, 25 count, NDC 00009-0870-26
    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL vial, 25 count, NDC 00009-0775-26
    • Cleocin injection, Pfizer, 150 mg/mL, 60 mL bulk vial, 5 count, NDC 00009-0728-09
    • Clindamycin phosphate injection, Akorn, 300 mg/50 mL, in 5% dextrose premixed bottle, 1 count, NDC 17478-0120-50
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL vial, 25 count, NDC 72611-0639-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL vial, 25 count, NDC 72611-0642-25
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 72611-0645-55
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9545-24
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3410-24
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9549-24
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3612-24
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9553-24
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3814-24
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 2 mL vial, 25 count, NDC 63323-0282-02
    • Clindamycin phosphate injection, Fresenius Kabi, 150 mg/mL, 6 mL vial, 25 count, NDC 63323-0282-06
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 25021-0115-51
    • Clindamycin phosphate injection, Sandoz, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3288-09
    • Clindamycin phosphate injection, Sandoz, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3289-09
    • Clindamycin phosphate injection, Sandoz, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3290-09

Estimated Resupply Dates

    • Akorn has clindamycin 600 mg/50 mL and 900 mg/50 mL in dextrose premixes on back order and the company cannot estimate a release date.
    • Almaject has discontinued clindamycin 150 mg/mL 2 mL, 4 mL, and 6 mL ADD-Vantage vials. Clindamycin 150 mg/mL 2 mL vials are short-dated with an expiration date of 9/30/2020.
    • Fresenius Kabi has short-dated clindamycin 150 mg/mL 4 mL and 60 mL vials available with an expiration date of <2 months.
    • Pfizer has Cleocin 150 mg/mL 2 mL, 4 mL, and 6 mL ADD-Vantage vials on back order and the company estimates a release date of June 2020. Clindamycin 150 mg/mL 6 mL vials are on intermittent back order.
    • Sagent has clindamycin 150 mg/mL 2 mL, 4 mL, and 6 mL vials on allocation.

Updated

Updated November 25, 2019 by Megan Dryer, PharmD. Created June 13, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins